Document Detail

Prasugrel: Clinical development and therapeutic application.
MedLine Citation:
PMID:  20020231     Owner:  NLM     Status:  MEDLINE    
Dual antiplatelet therapy with aspirin and clopidogrel is a cornerstone of the management of patients with acute coronary syndromes and following percutaneous coronary intervention. Despite the proven benefits, clear limitations of clopidogrel exist. Prasugrel is a third-generation thienopyridine antiplatelet agent with pharmacologic characteristics that overcome some of the limitations of clopidogrel, but at the expense of increased bleeding. The promising results seen with prasugrel in large, randomized trials led to its recent approval by the US Food and Drug Administration for reducing thrombotic cardiovascular events in patients with acute coronary syndromes managed with percutaneous coronary intervention. This article will review the limitations of standard antiplatelet therapy and discuss the clinical application of prasugrel.
Daniel R Guerra; James E Tcheng
Publication Detail:
Type:  Journal Article; Review     Date:  2009-12-17
Journal Detail:
Title:  Advances in therapy     Volume:  26     ISSN:  1865-8652     ISO Abbreviation:  Adv Ther     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2010-01-21     Completed Date:  2010-03-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  999-1011     Citation Subset:  T    
Cardiac Study Center, Tacoma, WA 98405, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Coronary Syndrome / complications,  drug therapy*
Angioplasty / adverse effects
Hemorrhage / chemically induced
Piperazines / administration & dosage,  adverse effects,  therapeutic use*
Platelet Aggregation Inhibitors / administration & dosage,  adverse effects,  therapeutic use*
Randomized Controlled Trials as Topic
Thiophenes / administration & dosage,  adverse effects,  therapeutic use*
Thrombosis / etiology,  prevention & control*
Ticlopidine / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Reg. No./Substance:
0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Thiophenes; 0/prasugrel; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis.
Next Document:  Changes in corneal endothelial cell density in patients with normal-tension glaucoma.